Abstract
BACKGROUND Helicobacter pylori (Hp) eradication therapy can alter gut microbiota, provoking gastro-intestinal (GI) symptoms that can be improved by probiotics. The effect on Hp patients of a Test fermented milk containing yogurt and three Lacticaseibacillus (L. paracasei CNCM I-1518, CNCM I-3689, L. rhamnosus CNCM I-3690) strains was assessed on antibiotic associated diarrhea (AAD) (primary aim), GI-symptoms, gut microbiota composition and metabolites. In this aim, a randomized, double-blind, controlled trial was performed in 136 adults under Hp-treatment (14-day amoxicillin, clarithromycin, pantoprazole), who consumed the Test or a Control product for 28 days. Feces were analysed for gut microbiota composition, short chain fatty acids (SCFA), calprotectin, and viability of ingested strains.
RESULTS No effect of Test product was observed on AAD occurrence or duration, rating scores or number of days of GI symptoms. Hp-treatment induced a significant alteration in bacterial and fungal composition, a decrease of bacterial count and alpha-diversity, an increase of Candida and of calprotectin, and a decrease of SCFA concentration. Following Hp treatment, in the Test as compared to Control group, intra-subject beta-diversity distance from baseline was lower (padj=0.02), Escherichia-Shigella (padj=0.0082) and Klebsiella (padj= 0.013) were significantly less abundant, and concentrations of major SCFA (p=0.035) and valerate (p = 0.045) were higher. Viable Lp and Lr strains from the Test product were mainly detected during product consumption in feces.
CONCLUSIONS The study showed that 14-day Hp triple therapy alters gut bacterial and fungal community, their metabolites and gut inflammatory markers. Consumption of a multi-strain fermented milk can induce faster recovery of the microbiota composition and SCFA production and limit the bloom of pathobionts. (ClinicalTrials.gov, NCT02900196; First Posted : September 14, 2016; https://www.clinicaltrials.gov/ct2/show/NCT02900196).
Competing Interest Statement
E.G, F.S, L.Q, CR, M.D, M.P are Danone Nutricia Research employees. FB received Grants from Astellas, Anios, MSD, Biomerieux, Quidel, Cubist, Biosynex, GenePoc, Personal fees from Astellas, Pfizer, MSD, Danone, and Non-financial support from Astellas, Pfizer, Anios, MSD. PM provide consultancies to AlfaSigma ,Bayer Vital, Danone, Luvos, Mayoly- Spindler, Menarini, Novartis and received speakers fee from Alfa Sigma, Bayer,Malesci, Mayoly-Spindler, Nordmark. HS has participated as a clinical investigator, and/or advisory board member, and/or consultant, and/or speaker for Arla, BioGaia, Biocodex, Danone, Dicofarm, Nestlé and Nestlé Nutrition Institute. CK and FW had no conflict of interest.
Clinical Trial
NCT02900196
Funding Statement
The study was funded by Danone Nutricia Research (France).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Charité Campus Mitte (Application Number EA1/297/15) of the Charité Universitatsmedizin Berlin, Germany.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* co-last
Other author’s emails: Marion Poirel: Marion.POIREL{at}external.danone.com
Florent Schäfer: Florent.SCHAFER{at}danone.com
Laurent Quinquis: Laurent.QUINQUIS{at}danone.com
Caroline Rossoni: caroline.rossoni{at}external.danone.com
Christian Keicher: Christian.Keicher{at}charite-research.org
Frank Wagner: Frank.Wagner{at}charite-research.org
Hania Szajewska: hania{at}ipgate.pl
Frédéric Barbut: frederic.barbut{at}aphp.fr
Muriel Derrien: Muriel.DERRIEN{at}danone.com
Abbreviations
- AAD
- antibiotic associated diarrhea
- BSS
- Bristol Stool Scale
- AE
- Adverse Event
- Cd
- Clostridioides difficile
- CDAD
- Cd-associated diarrhea
- GI
- gastro-intestinal
- GSRS
- Gastrointestinal Symptom Rating Scale
- Hp
- Helicobacter pylori
- ICF
- Informed Consent Form
- Lp
- Lacticaseibacillus paracasei
- Lr
- Lacticaseibacillus rhamnosus
- PcoA
- Principal Coordinate analysis
- QMP
- Quantitative Microbiome Profiling
- SCFA
- short chain fatty acids
- rRNA
- ribosomal RNA
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos